SobiTM to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth
(WorldNews Sweden)

Tue, 11/13/2018 - 08:00 Regulatory SobiTM to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth SobiTM to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth Swedish Orphan Biovitrum AB (publ)(SobiTM) (STO:SOBI) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to USD 1,500 M (SEK 13.6 B[1]), consisting of USD 1,000 M (SEK 9.1 B) in cash and USD 500 M (SEK 4.5 B) equivalent in newly issued Sobi shares. In addition, deferred and...